Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

0000950170-25-024119.txt

BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more BridgeBio Pharma Charts.

BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more BridgeBio Pharma Charts.

BridgeBio Pharma Inc News

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Thursday 20 February 2025 (3 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 20 February 2025 (3 days ago) • Edgar (US Regulatory)

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
Thursday 20 February 2025 (3 days ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 19 February 2025 (4 days ago) • Edgar (US Regulatory)

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
Thursday 13 February 2025 (1 week ago) • GlobeNewswire Inc.

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
Tuesday 11 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 30 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 28 January 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 13 January 2025 (1 month ago) • Edgar (US Regulatory)

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
Monday 13 January 2025 (1 month ago) • GlobeNewswire Inc.

More BridgeBio Pharma Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions